SourceOne Global Partners (“SourceOne”) has announced it has reached a global cannabis commercialization agreement with NanoLeaf Technologies Inc. (Toronto, Ontario) to grant access to the patented VESIsorb® advanced delivery system in Canada with strategic expansion in key markets including Europe, Israel and South America. Per the agreement, SourceOne will supply VESIsorb® for use with cannabis for human consumption.
SourceOne’s decision for the commercialization agreement is based on NanoLeaf’s commitment to building an immediate infrastructure for Canadian market leadership and long-term global reach as well as Canada’s commitment to comprehensive cannabis legalization, pursuit of new clinical research and access to banking and investment, according to Jesse Lopez, CEO and founder of SourceOne.
Lopez commented, “This agreement further positions VESIsorb® as the leading advanced delivery system for dramatically improving absorption and bioavailability of poorly absorbed ingredients, like phytocannabinoids.”
VESIsorb® is a naturally self-assembling colloidal droplet delivery system that has been clinically proven to increase absorption of bioactives used in nutritional supplements, functional food and beverages, cosmetics, medical foods and pharmaceutical products. Multiple studies have demonstrated the benefits of VESIsorb®, an innovative drug delivery system with a robust portfolio of patents and patents-pending.
Dr. James Hyssen, CEO of NanoLeaf, commented, “We chose to partner with SourceOne in order to gain access to the highly sought-after patented VESIsorb® drug delivery technology that is currently used by large, global companies. This impressive portfolio of VESIsorb® patents and proven technology will enable us to expand our suite of bioavailable cannabis products and deliver entry into new markets while providing the widest range of product applications that are ready to be commercially developed and meet marketplace needs.”
In 2007, SourceOne formed an exclusive worldwide partnership with Vesifact AG (Baar, Switzerland) for VESIsorb®. After immediately launching a bio-enhanced coenzyme Q10, SourceOne’s product portfolio featuring VESIsorb® quickly evolved into the widest range of the most popular science-backed bioactive ingredients like concentrated omega-3 EFAs, QH ubiquinol Q10, vitamin K2, curcumin, vitamin D, pterostilbene, pyrroloquinoline quinone (PQQ), palm tocotrienols, diindolylmethane (DIM), gamma tocopherols, citrus polymethoxylated flavones (PMFs), resVida® and resveratrol, among others.
Marc Weder, CEO of Vesifact, observed, “There continues to be a growing pipeline of VESIsorb® formulations, and the importance of pioneering the bioavailability and efficacy of poorly-absorbed nutrients, like phytocannabinoids, has never been greater.”
“Together, Vesifact and SourceOne’s goal is to partner with companies that focus on innovation, clinical research and market leadership while having the financial strength to build awareness and educate consumers. NanoLeaf had all the critical elements we were looking for to champion the VESIsorb® drug delivery technology in the emerging global cannabis market,” added Weder.
As consumer demand for bio-enhanced cannabis products continues to grow worldwide, Lopez said, SourceOne is supremely positioned to deliver VESIsorb® in a wide range of patent-protected formulas and applications such as soft gels, hard shell capsules, tinctures, edibles, lotions, stick packs, wellness shots, sprays, and much more.